Skip to main content
SpringerLink
Log in

Parkinsonian Drugs in China

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 162 Accesses

Abstract

Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by continuous neuronal loss in the substantia nigra. During the past decade, there has been a remarkable progress in our understanding of the pathogenesis of PD, which has been translated into searching for therapy against PD. The therapeutic approaches include relieving PD symptoms such as levodopa replacement therapy and neuroprotective therapy aiming to protect dopaminergic neurons and modify the disease course. In addition, several kinds of traditional Chinese herbs also showed effectiveness in delaying disease progression both in vivo and vitro. Furthermore, the Chinese Parkinson’s Disease and Movement Disorder Society has published three versions of guidelines for the management of PD in China, in 2006, 2009, and 2014. Since then, the overall level of treatment for PD in China has been significantly improved. In this chapter, we will review the pharmacological treatment for PD in China as well as current neuroprotective therapy against this disease. With the new knowledge and understanding of the PD etiology, we believe that more and more new drugs aimed at both controlling symptoms and preventing PD and retarding the progression of the disease will come on the market soon.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Akao Y, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. J Neurochem. 2001;78:727–35.

    Article  Google Scholar 

  • Berker G, et al. Early diagnosis of Parkinson’s disease. J Neurol. 2003;249(Suppl 3):40–8.

    Google Scholar 

  • Bezard E, et al. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577–88.

    Article  CAS  Google Scholar 

  • Chen S, Le W. Neuroprotective therapy in Parkinson disease. Am J Ther. 2006;13(5):445–57.

    Article  Google Scholar 

  • Chen S, et al. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett. 2008;582(5):603–10.

    Article  CAS  Google Scholar 

  • Chen S, et al. The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease. Transl Neurodegener. 2016;5:12.

    Article  Google Scholar 

  • Deng YN, et al. Celastrol protects human neuroblastoma SH-SY5Y cells from rotenone-induced injury through induction of autophagy. Neurochem Int. 2013;63:1–9.

    Article  CAS  Google Scholar 

  • Dewey RB. Management of motor complications in Parkinson’s disease. Neurology. 2004;62(Suppl 4):S3–7.

    Article  Google Scholar 

  • Giasson BI, Lee VM. Parkin and the molecular pathways of Parkinson’s disease. Neuron. 2001;31:885–8.

    Article  CAS  Google Scholar 

  • Grunblatt E, et al. Apomorphine protects against MPTP-induced mice. Mov Disord. 1999;14:612–8.

    Article  CAS  Google Scholar 

  • Guo SS, et al. Ganoderma Lucidum polysaccharides protect against MPP(+) and rotenone-induced apoptosis in primary dopaminergic cell cultures through inhibiting oxidative stress. Am J Neurodegener Dis. 2016;5:131–44.

    PubMed  PubMed Central  Google Scholar 

  • Hardy J. Impact of genetic analysis on Parkinson’s disease research. Mov Disord. 2003;18 (Suppl 6):S96–8.

    Article  Google Scholar 

  • Hölscher C, et al. Are Alzheimer’s disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones? Neuropharmacology. 2018;136(Pt B):159.

    Article  Google Scholar 

  • Im JH, et al. Ropinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: a 16-week bromocriptine controlled study. J Neurol. 2003;250:90–6.

    Article  Google Scholar 

  • Ji H-F, et al. The multiple pharmaceutical potential of curcumin in Parkinson’s disease. CNS Neurol Disord Drug Targets. 2014;13:369–73.

    Article  CAS  Google Scholar 

  • Joyce JN, et al. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson’s disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol. 2004;2:22.

    Article  Google Scholar 

  • Kim T, et al. In vitro generation of mature midbrain-type dopamine neurons by adjusting exogenous Nurr1 and Foxa2 expressions to their physiologic patterns. Exp Mol Med. 2017;49(3):e300.

    Article  CAS  Google Scholar 

  • Le WD, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003;33:85–9.

    Article  CAS  Google Scholar 

  • Lewitt PA, Nyholm D. New developments in levodopa therapy. Neurology. 2004;62(Suppl 1):S9–S17.

    Article  CAS  Google Scholar 

  • Muralikrishnan D, et al. Neuroprotection by bromocriptine against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J. 1998;12:905–12.

    Article  CAS  Google Scholar 

  • Mythri RB, et al. Curcumin: a potential neuroprotective agent in Parkinson’s disease. Curr Pharm Des. 2012;18(1):91–9.

    Article  CAS  Google Scholar 

  • Nitta A, et al. Brain-derived neurotrophic factor prevents neuronal cell death induced by corticosterone. J Neurosci Res. 1999;57(2):227–35.

    Article  CAS  Google Scholar 

  • Nutt JG, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69–73.

    Article  CAS  Google Scholar 

  • Obeso JA, et al. Pathophysiology of levodopa-induced dyskinesia in Parkinson’s disease: problems with current models of the basal ganglia. Ann Neurol. 2000;47:22–34.

    Google Scholar 

  • Obeso JA, et al. The origin of motor fluctuations in Parkinson’s disease. Neurology. 2004;62 (Suppl 1):S17–30.

    Article  CAS  Google Scholar 

  • Palhagen S, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology. 1998;51:520–5.

    Article  CAS  Google Scholar 

  • Pan T, et al. Potential therapeutic properties of green tea polyphenols in Parkinson’s disease. Drugs Aging. 2003;20:711–21.

    Article  CAS  Google Scholar 

  • Rojas P, et al. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci. 2008;28:41–50.

    Article  Google Scholar 

  • Roussa E, et al. GDNF promotes neuronal differentiation and dopaminergic development of mouse mesencephalic neurospheres. Neurosci Lett. 2004;361(1–3):52–5.

    Article  CAS  Google Scholar 

  • Shan C-S, et al. Herbal medicine formulas for Parkinson’s disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled clinical trials. Front Aging Neurosci. 2018;10:349.

    Article  CAS  Google Scholar 

  • Shimura H, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science. 2001;293(5528):263–9.

    Article  CAS  Google Scholar 

  • Stocchi F, et al. Advances in dopamine receptor agonists for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2016;17(14):1889–902.

    Article  CAS  Google Scholar 

  • Wagner J, et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol. 1999;17(7):653–9.

    Article  CAS  Google Scholar 

  • Wang Y, et al. Chinese herbal medicine paratherapy for Parkinson’s disease: a meta-analysis of 19 randomized controlled trials. Evid Based Complement Alternat Med. 2012;2012:534861.

    PubMed  PubMed Central  Google Scholar 

  • Wang YQ, et al. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson’s disease model induced by MPTP via chelating iron. Free Radic Res. 2015;49:1069–80.

    Article  CAS  Google Scholar 

  • Zhang G, et al. Effectiveness of traditional Chinese medicine as an adjunct therapy for Parkinson’s disease: a systematic review and meta-analysis. PLoS One. 2015;10:e0118498.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    Sheng Chen & Yining Gao

  2. Department of Neurology, Shanghai 6th People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    Xiaojie Zhang

  3. The First Affiliated Hospital, Dalian Medical University, Dalian, China

    Weidong Le

Authors
  1. Sheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaojie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yining Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weidong Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weidong Le .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Chen, S., Zhang, X., Gao, Y., Le, W. (2020). Parkinsonian Drugs in China. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_290-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_290-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation